5 Key Takeaways

• 1

  Melatonin shows potential as an adjunctive therapy for systemic lupus erythematosus due to its antioxidant and anti-inflammatory properties.

• 2

  A randomized trial indicated that melatonin supplementation reduced serum malondialdehyde levels in systemic lupus erythematosus patients.

• 3

  Lower serum melatonin levels in systemic lupus erythematosus patients correlate inversely with disease activity, suggesting its diagnostic potential.

• 4

  Melatonin administration in animal models reduced renal damage in lupus nephritis by modulating protein expression related to inflammation.

• 5

  Further research is necessary to optimize melatonin dosing regimens and evaluate its long-term efficacy as an adjunctive therapy.